Eckert & Ziegler stock rises 1.51% since prior report on Ac-225

Published on 11/03/2026 at 18:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock advances after a fresh trading comparison. GMP approval supports clinical supply and planned Ac-225 capacity expansion.

Ac-225 approval supports supply plans

Eckert & Ziegler received GMP authorization for Actinium-225 production through its wholly owned subsidiary.
The production chain links radium-226 irradiation in the Czech Republic with processing in Braunschweig.
Expansion plans include a commercial-scale Ac-225 site in China after initial operations expected in early 2027.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler stock has gained 1.51 percent since the company-related report published on Monday, November 2, at 14:15. The latest quote also reflects continued investor attention to the group's Actinium-225 production plans.

The real-time quote of Eckert & Ziegler stock stood at 13.45 euros on Lang & Schwarz at 18:07 CET on Tuesday, November 3, 2026, 0.45 percent above the Xetra close of Tuesday, November 3. The previous report had cited 13.25 euros at 14:06 CET on November 2.

GMP approval moves Ac-225 toward supply

On October 28, Eckert & Ziegler Therapeutics GmbH received manufacturing authorization for Actinium-225 from the competent German authority. The company's official announcement said the certification confirms compliance with Good Manufacturing Practice requirements and facilitates investigational patient treatment.

Production begins with cyclotron-based irradiation of radium-226 at the Czech Academy of Sciences' Nuclear Physics Institute in Rež. The irradiated material is then processed at Eckert & Ziegler's Braunschweig site. The company said its process keeps long-lived impurities such as Actinium-227 and Thorium-229 to a minimum.

Capacity plans extend beyond Germany

The group is also preparing a broader supply network. Its Qi Kang Medical Technology joint venture in Jintan, China, is intended to become the country's first commercial-scale Ac-225 production site after initial operations start in early 2027. Further capacity near Boston and in Germany remains under consideration.

The approval improves the industrial basis for clinical supply, but the financial contribution will depend on production volumes, customer programs and the pace of commercial adoption. The announcement did not provide revenue guidance or contracted sales volumes.